UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The New Big Is Small: Leveraging Knowledge from Small Trials for Rare Disease Drug Development - Blarcamesine for Rett Syndrome

British journal of clinical pharmacology, 2023-08

2023

Volltextzugriff (PDF)

Pharmacometrics: the science of quantitative pharmacology

1, 2007

Volltextzugriff (PDF)

Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy

BMC pediatrics, 2023-01, Vol.23 (1), p.24-8, Article 24

2023

Volltextzugriff (PDF)

Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome

Epilepsy research, 2019-11, Vol.157, p.106182-106182, Article 106182

2019

Volltextzugriff (PDF)

Predictors of gentamicin therapy failure in neonates with sepsis

Pharmacology research & perspectives, 2024-08, Vol.12 (4), p.e1250-n/a

2024

Volltextzugriff (PDF)

Confirming the Suitability of a Gentamicin Dosing Strategy in Neonates Using the Population Pharmacokinetic Approach with Truncated Sampling Duration

Children (Basel), 2024-07, Vol.11 (8), p.898

2024

Volltextzugriff (PDF)

Population‐Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease

Clinical pharmacology in drug development, 2024-01, Vol.13 (1), p.21-31

2024

Volltextzugriff (PDF)

Maximizing Knowledge Extraction From Patient‐Reported Outcome Data Using Exposure‐Outcome Item Response Modeling Approach: Understanding Efavirenz‐Induced Central Nervous System Toxicity

Journal of clinical pharmacology, 2020-06, Vol.60 (6), p.711-721

2020

Volltextzugriff (PDF)

A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro

In silico pharmacology, 2023-10, Vol.11 (1), p.31, Article 31

2023

Volltextzugriff (PDF)

Population pharmacokinetics I: background, concepts, and models

The Annals of pharmacotherapy, 2004-10, Vol.38 (10), p.1702-1706

2004

Volltextzugriff (PDF)

Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions

Journal of clinical pharmacology, 2016-03, Vol.56 (3), p.365-374

2016

Volltextzugriff (PDF)

Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

Journal of clinical pharmacology, 2015-11, Vol.55 (11), p.1229-1235

2015

Volltextzugriff (PDF)

An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics

Journal of clinical pharmacology, 2016-02, Vol.56 (2), p.213-222

2016

Volltextzugriff (PDF)

Transition modeling of neuropsychiatric impairment in HIV

Computers in biology and medicine, 2016-06, Vol.73, p.141-146

2016

Volltextzugriff (PDF)

Population pharmacokinetics II: estimation methods

The Annals of pharmacotherapy, 2004-11, Vol.38 (11), p.1907-1915

2004

Volltextzugriff (PDF)

Stimulus – Response mechanistic modeling of pharmacodynamic drug-drug interaction: Extension of the operational receptor model of agonism

Informatics in medicine unlocked, 2022, Vol.28, p.100813, Article 100813

2022

Volltextzugriff (PDF)

Model Appropriateness and Population Pharmacokinetic Modeling

Journal of clinical pharmacology, 2003-06, Vol.43 (6), p.610-623

2003

Volltextzugriff (PDF)

Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies

The Annals of pharmacotherapy, 2004-12, Vol.38 (12), p.2136-2144

2004

Volltextzugriff (PDF)

Stability and Performance of a Population Pharmacokinetic Model

Journal of clinical pharmacology, 1997-06, Vol.37 (6), p.486-495

Ette, Ene I.

1997

Volltextzugriff (PDF)

A pragmatic approach to the design of population pharmacokinetic studies

The AAPS journal, 2005-10, Vol.7 (2), p.E408-E420

2005

Volltextzugriff (PDF)

Pharmacometrics of Clobazam in Pediatrics: Population PK Modeling to Predict Effective Clobazam Doses for Dravet Syndrome (P4.265)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel

Clinical cancer research, 2002-03, Vol.8 (3), p.670-678

2002

Volltextzugriff (PDF)

Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma

Clinical cancer research, 2002-02, Vol.8 (2), p.383-393

2002

Volltextzugriff (PDF)

Conscience, the law, and donation of expired drugs

The Annals of pharmacotherapy, 2004-07, Vol.38 (7-8), p.1310-1313

Ette, Ene I

2004

Volltextzugriff (PDF)

PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE THERAPEUTIC EFFECT OF ORAL P38 MAPK ALPHA ANTAGONISM ON EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE (AD)

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P669-P669

2018

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(86)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(120)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(50)
Science & Technology
(50)
Humans
(39)
Pharmacology & Pharmacy
(38)
Pharmacokinetics
(29)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Pharmacology. Drug Treatments
(26)
Adult
(19)
Female
(17)
Male
(17)
General Pharmacology
(13)
Models, Biological
(12)
Middle Aged
(11)
Pharmacokinetics. Pharmacogenetics. Drug-Receptor Interactions
(11)
Population Pharmacokinetics
(11)
Aged
(9)
Nonmem
(8)
Research Design
(8)
Drug Interactions
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The New Big Is Small: Leveraging Knowledge from Small Trials for Rare Disease Drug Development - Blarcamesine for Rett Syndrome

Pharmacometrics: the science of quantitative pharmacology

Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy

Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome

Predictors of gentamicin therapy failure in neonates with sepsis

Confirming the Suitability of a Gentamicin Dosing Strategy in Neonates Using the Population Pharmacokinetic Approach with Truncated Sampling Duration

Population‐Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease

Maximizing Knowledge Extraction From Patient‐Reported Outcome Data Using Exposure‐Outcome Item Response Modeling Approach: Understanding Efavirenz‐Induced Central Nervous System Toxicity

A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro

Population pharmacokinetics I: background, concepts, and models

Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions

Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy

An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics

Transition modeling of neuropsychiatric impairment in HIV

Population pharmacokinetics II: estimation methods

Stimulus – Response mechanistic modeling of pharmacodynamic drug-drug interaction: Extension of the operational receptor model of agonism

Model Appropriateness and Population Pharmacokinetic Modeling

Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies

Stability and Performance of a Population Pharmacokinetic Model

A pragmatic approach to the design of population pharmacokinetic studies

Pharmacometrics of Clobazam in Pediatrics: Population PK Modeling to Predict Effective Clobazam Doses for Dravet Syndrome (P4.265)

Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel

Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma

Conscience, the law, and donation of expired drugs

PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE THERAPEUTIC EFFECT OF ORAL P38 MAPK ALPHA ANTAGONISM ON EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE (AD)

Suchergebnisse filtern